Liposyn Iii 30% is a drug owned by Hospira Inc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 08, 2033. Details of Liposyn Iii 30%'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9717852 | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Liposyn Iii 30%'s patents.
Latest Legal Activities on Liposyn Iii 30%'s Patents
Given below is the list of recent legal activities going on the following patents of Liposyn Iii 30%.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Sep, 2020 | US9717852 |
| Recordation of Patent Grant Mailed Critical | 01 Aug, 2017 | US9717852 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Aug, 2017 | US9717852 |
| Issue Notification Mailed Critical | 12 Jul, 2017 | US9717852 |
| Dispatch to FDC | 05 Jul, 2017 | US9717852 |
| Mail Response to 312 Amendment (PTO-271) Critical | 05 Jul, 2017 | US9717852 |
| Response to Amendment under Rule 312 Critical | 05 Jul, 2017 | US9717852 |
| Amendment after Notice of Allowance (Rule 312) Critical | 26 Jun, 2017 | US9717852 |
| Workflow - Drawings Finished | 26 Jun, 2017 | US9717852 |
| Mail PUB other miscellaneous communication to applicant | 22 Jun, 2017 | US9717852 |
US patents provide insights into the exclusivity only within the United States, but Liposyn Iii 30% is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Liposyn Iii 30%'s family patents as well as insights into ongoing legal events on those patents.
Liposyn Iii 30%'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Liposyn Iii 30%'s generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 08, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Liposyn Iii 30% Generics:
There are no approved generic versions for Liposyn Iii 30% as of now.
Alternative Brands for Liposyn Iii 30%
There are several other brand drugs using the same active ingredient (Soybean Oil) as Liposyn Iii 30%. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Baxter Hlthcare Corp |
|
About Liposyn Iii 30%
Liposyn Iii 30% is a drug owned by Hospira Inc. Liposyn Iii 30% uses Soybean Oil as an active ingredient. Liposyn Iii 30% was launched by Hospira in 1998.
Approval Date:
Liposyn Iii 30% was approved by FDA for market use on 13 January, 1998.
Active Ingredient:
Liposyn Iii 30% uses Soybean Oil as the active ingredient. Check out other Drugs and Companies using Soybean Oil ingredient
Dosage:
Liposyn Iii 30% is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30% | INJECTABLE | Discontinued | INJECTION |